Newsroom | 49902 results

RALEIGH, N.C.--(BUSINESS WIRE)--Caidya Announces Michael Clay as Chief Operating Officer....

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2025, after the market closes on Feb. 26, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera’s Fourth Quarter & Full Year 2025 Financial Results Date: February 26, 2026 Time: 1:30 p.m....

SAN DIEGO--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced the publication of a peer-reviewed study in EP Europace evaluating vMap-guided activation mapping and ablation in patients with hemodynamically unstable ventricular tachycardia (VT). The study, titled “Artificial Intelligence ECG Localization Facilitates Focused Activation Mapping and Improves Outcomes in Hemodynamically Unstable Ventricular Tachycardia,” demonstrated t...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros’ OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial si...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities affected by HIV, notable late-breaking abstra...

LOS ANGELES--(BUSINESS WIRE)--The Prostate Cancer Foundation (PCF) today announced $6.3 million in funding for 31 exceptional Young Investigators pursuing groundbreaking discoveries in prostate cancer. Since 1993, PCF’s prestigious early-career awards program has identified and supported the world’s brightest emerging researchers, providing critical funding and mentorship to accelerate clinical innovation and patient care. "Every breakthrough begins with a brilliant mind and a bold new idea," s...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of cataplexy in pediatric patients 6 years of age and older with narcolepsy. WAKIX is now the first-and-only FDA-approved non-scheduled treatment for pediatric and adult narcolepsy patients with or without cataplexy. “We are excited to achieve this im...

SOUTH SAN FRANCISCO, Calif--(BUSINESS WIRE)--Circle Pharma, Inc. announced management will participate in upcoming investor conferences in February and March....

SAN ANTONIO, Texas--(BUSINESS WIRE)--bioAffinity Technologies shares a new case study that demonstrates how CyPath® Lung supports clinical decision-making in high-risk patients....

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data presentations from its innovative HIV treatment and prevention portfolio and integrase inhibitor (INSTI)-led pipeline at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado from 22-25 February. Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said: “We are making major advanc...